Jeff Hall

New research revealed no significant difference between gadolinium-free MRI and GBCA-enhanced MRI in preoperative predictive accuracy for the grading of diffuse gliomas in adults.

For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.

The updated software reportedly provides access to more than 200 enhanced features including optimized hanging protocols with a cardiac MRI viewer and perfusion quantification analysis.

A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.

The Gentuity HF-OCT Imaging System, which includes the 1.8 F Vis-Rx Micro-Imaging Catheter, is reportedly the first intravascular imaging system to garner a specific indication for pre- and post-intervention assessments of coronary vessels.

The Ezra Blueprint scan reportedly includes quantitative brain measurements, coronary calcium scoring (CAC) and a full-body MRI that provides screening for over 500 conditions.

Earlier detection of PSMA-avid lesions in post-radiotherapy patients with increases in PSA levels < 2 ng/ml above nadir were reportedly associated with a significantly lower incidence of distant metastases and lower overall mortality rates.

Designed for theranostic imaging applications, the AnyScan Trio SPECT/CT TheraMax scanner was recently unveiled at the annual meeting of the European Association of Nuclear Medicine (EANM).

For segment-level coronary artery calcium (CAC) scoring, a deep learning model had an accuracy rate of 73 percent for assigning calcifications to coronary artery segments and achieved a micro-average specificity of 97.8 percent.

Offering standardized assessment of amyloid plaque and insights on tau protein tangles, the newly clearly FDA features of Centiloid scoring and tau PET quantification with syngo.PET Cortical Analysis software may facilitate diagnosis of Alzheimer’s disease.

Adjunctive use of deep learning reportedly led to a 37 percent reduction of interpretation time for cerebral aneurysm assessment on computed tomography angiography (CTA) and greater than a 90 percent reduction in post-processing time.

Examining six comparative studies within a new meta-analysis, researchers found that FAPI PET/CT offered 11 percent higher pooled sensitivity and 28 percent higher pooled specificity than FDG PET/CT for diagnosing lymph node metastases in patients with lung cancer.

When employing a PI-RADS > 4 cutoff, researchers found that the mdprostate software provided an 85.5 percent sensitivity rate for diagnosing clinically significant prostate cancer on mpMRI.

Leveraging AI technology, the AiMIFY software reportedly facilitates double the contrast enhancement in comparison to gadolinium-based contrast agents (GBCAs) for brain MRI.

The Sonire Therapeutics ultrasound system is currently being studied for the treatment of patients with unresectable pancreatic cancer refractory or intolerant to first-line chemotherapy.

In nearly 5,300 patients with suspected coronary artery disease (CAD), adjunctive use of CT-based fractional flow reserve software significantly reduced the 90-day invasive coronary angiography (ICA) rate in comparison to unassisted use of coronary computed tomography angiography (CCTA).

The new ultrasound platform reportedly offers a combination of enhanced imaging and AI-enabled tools to facilitate improved workflow efficiency.

Four Medicare administrative contractors (MACs) will provide coverage of AI-enabled coronary plaque analysis and quantitative coronary tomography assessment of coronary computed tomography angiography (CCTA) for Medicare beneficiaries starting in November 2024.

For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.

New research suggests that reviewing mammography images in order of ascending volumetric breast density as opposed to random reading of exams demonstrated reduced reading time and less fixation time on malignant lesions.

Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.

Researchers found that ultra-high resolution photon-counting significantly enhanced visualization of small vessels and facilitated improved reduction of blooming artifacts for head and neck computed tomography angiography (CTA) scans.

The combination of FDA-cleared AI software for mammography triage with a medical grade edge AI platform may allow the embedding of enhanced AI detection capability within existing mammography devices.

A symptomatic first breast cancer diagnosis, prevailing breast density at a second breast cancer diagnosis and trabecular thickening on surveillance mammography were linked to mammogram-occult ipsilateral breast cancer, according to new research.

Based off rapid magnetic resonance imaging (MRI), the AI-enabled MuscleView reportedly offers 3D analysis of muscle volume, muscle asymmetry and intramuscular fat.

In a multicenter study of over 370 women who had surgery for ovarian cystic lesions without acute symptoms, researchers found that 42 percent of the resected lesions were deemed to have an O-RADS ultrasound risk score of 2, which has less than a one percent chance of malignancy.

With the capability of identifying possible cases of aortic value stenosis (AVS) from existing electrocardiograms (ECGs), the AI-powered screening software from AccurKardia may facilitate earlier diagnosis of AVS, which is fatally missed in 50 percent of patient who have this condition.

PSMA PET/CT revealed progressive PCa in 31 percent of patients who demonstrated greater than a 50 percent decline in PSA level after treatment with either an androgen receptor-targeted agent or chemotherapy.

The clearance may facilitate improved standardization and efficiency of dosimetry-guided, theranostic applications of radiopharmaceutical therapy.

In a study looking at the impact of experience and case volume of breast screening radiologists, researchers found that reviewing more than 150 cases per week was necessary to achieve an 80 percent rate of true-positive assessments for malignant calcifications.